BCS3: A New Drug to Fight Breast Cancer
Author Information
Author(s): Acharya Reetuparna, Deb Pran Kishore, Venugopala Katharigatta N., Pattanayak Shakti Prasad
Primary Institution: Birla Institute of Technology (BIT), Mesra, Ranchi, India
Hypothesis
Can the azomethine derivative BCS3 effectively target IAPs to inhibit breast cancer progression?
Conclusion
BCS3 shows significant anti-proliferative effects on breast cancer cells and has a favorable safety profile.
Supporting Evidence
- BCS3 showed strong selective cytotoxic activity against breast cancer cell lines.
- In vivo studies demonstrated reduced tumor volume and improved body weight in treated rats.
- BCS3 effectively modulated apoptotic pathways by inhibiting IAPs.
Takeaway
BCS3 is a new medicine that helps stop breast cancer cells from growing by making them die, and it seems to be safe for the body.
Methodology
The study involved designing and synthesizing BCS3, followed by in vitro and in vivo testing on breast cancer cell lines and animal models.
Limitations
The study primarily focused on specific breast cancer cell lines and may not represent all breast cancer types.
Statistical Information
P-Value
1.554 µM, 5.979 µM, 6.462 µM
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website